IMPAACT 2010 Screening Visits

Slides:



Advertisements
Similar presentations
1 MTN-003 Training Follow-up Visit Scheduling and Visit Coding SSP Sections and
Advertisements

ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
Contraception/Pregnancies MTN 020. Why do we care? Participants must come off product during pregnancy and breastfeeding – Studies of dapivirine in pregnant.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Overview of Enrollment Procedures. Training Materials for this session  All materials for this session can be found under the Enrollment tab of your.
Baseline Medical and Menstrual History The ins, outs, ups, and downs of collecting a relevant and complete baseline medical/menstrual history MTN 020 Training.
MTN-025/HOPE Decliner Population Procedures. Who are the Decliner Population? Former ASPIRE participants who decline or express no interest in joining.
Maternal clinical considerations
IMPAACT 2010 Eligibility Criteria
Maternal Toxicity Management
Maternal clinical considerations
IMPAACT 2010 Protocol Specifications for Recruitment, Screening, and Enrollment No updates.
Clinical Case Scenarios
Infant Surface Exams: Procedures, Source Documents, Photos, and eCRFs
The Role and Responsibilities of the Clinical Research Coordinator
Planning for HOPE PUEVs and Study Exit Visits
5 Day Forecast Mon Tues Wed Thu Fri.
Overview of Visit Scheduling and Types of Follow-up Visits SCHARP
IMPAACT 2010 Screening Visits
Maternal Schedule of Evaluation
IMPAACT 2010 Eligibility Criteria
VESTED Quiz Game
Infant clinical considerations
Clinicaltrials.gov Update
ARC Chairperson Training
Clinical Case Scenarios
Delivery Visits: Key Concepts and Procedures
IFSP Aligned with the Early Intervention Data System
VESTED Quiz Game
Maternal Toxicity Management
Expedited Adverse Event Reporting Requirements
Maternal Toxicity Management
Maternal clinical considerations
Infant clinical considerations
Protocol References Section Title 6.2 Entry Visit 5.1
Clinical Case Scenarios
Clinical Case Scenarios
Protocol References Section Title 6.2 Entry Visit 5.1
Delivery Visits: Key Concepts and Procedures
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Screening Visits
Expedited Adverse Event Reporting Requirements
IMPAACT 2010 Pharmacy, Study Drug, and Concomitant Medication Considerations at Entry No updates.
New IFSP – Policy and Procedures Update
MTN-037 Screening and Enrollment
ARCADIA Coordinator Webinar
Overview of Enrollment Procedures
Research Proposal Data collection Components of the study
MTN-020 Common QCs and Form Completion Questions
HIV Counseling.
ARC Chairperson Training
MON TUE WED THU
HOW TO ENTER BASELINE DATA
First Antenatal Assessment
Participant Retention
Obtaining Informed Consent
2008 Calendar.
Case reports and sites activities
Sun Mon Tue Wed Thu Fri Sat
Revised Common Rule: Informed Consent Changes
Sun Mon Tue Wed Thu Fri Sat
1/○~1/○ weekly schedule MON TUE WED THU FRI SAT SUN MEMO
TRACE INITIATIVE: Practical Scenarios
2016 | 10 OCT SUN MON TUE WED THU FRI SAT
Sun Mon Tue Wed Thu Fri Sat
TRACE INITIATIVE: HIV Testing Services (HTS)
2008 Calendar.
Presentation transcript:

IMPAACT 2010 Screening Visits Maybe re-assign teams after lunch

Protocol References Section Title 6.1 Screening Visits Appendix 1 Schedule of Evaluations ─ Antepartum

Screening Visits Key operational reminders: Screening may be initiated after written informed consent is obtained Screening procedures must be performed within 14 days prior to enrollment Screening procedures may be performed on multiple days, including on the date of enrollment Screening procedures may be repeated, with the latest outcome used for eligibility determination

Repeat Screening Attempts If the 14-day screening period is exceeded, the screening process may be repeated, if adequate time remains to permit enrollment within 14 days of non-study ART initiation. In this case, all procedures listed in protocol Section 6.1, including the informed consent process, must be repeated except: New PIDs should not be assigned Confirmatory HIV testing need not be repeated Fetal ultrasound need not be repeated Previously documented medical and medications history information should be reviewed and updated through the date of re-screening (it is not necessary to re-record history information that was previously documented) Section 6.1, bottom of page 54

A mother’s baseline medical history is first recorded at the Screening Visit. True False

Where in the protocol can you find the required elements of the maternal baseline medical history? Section 6.11 Text and Table 3

A complete maternal physical exam is required at the Screening Visit. True False

Where in the protocol can you find the required elements of the complete maternal physical exam? Section 6.12

Fetal ultrasound must be performed within 14 days prior to enrolment. True False

Fetal Ultrasound Fetal ultrasound should be performed if possible during the study screening period to: Estimate gestational age Assess for multiple gestation and fetal anomalies If ultrasound is performed during the screening period, results must be considered for purposes of eligibility determination If ultrasound cannot be performed during the screening period (should be rare), the best available method should be used to perform these assessments for purposes of eligibility determination

Fetal Ultrasound If a fetal ultrasound is not performed prior to entry, it must be done as soon as possible and within 14 days after study entry Ultrasound findings will then be used in algorithms to calculate gestational age at study entry and at delivery If a fetal ultrasound is performed after entry, enrolled participants will not be withdrawn from the study if the ultrasound identifies an exclusionary condition

AST and ALT test results must be available prior to enrollment. True False 4.1.4

If an exclusionary ALT result is obtained at screening, the test may be repeated, with the latest outcome used for eligibility determination. True False 4.1.4

When can enrollment occur? SUN MON TUE WED THU FRI SAT 1 Starts ART 2 3 Screening Visit 4 5 6 7 8 Screening lab results received 9 10 11 12 13 14 Last day to enroll 15 16 17 18 19 20 21 22 23 24 25 26 In this example, we have the same ART initiation and screening visit dates as in previous examples, so we know that the last day to enroll falls on the 14th of the month. We have also noted in this example that screening lab results are received on the 8th of the month. Looking at the calendar, we need to consider whether there enough time to recall the participant to the clinic and repeat the tests, with results received before the last day to enroll. This may or may not be possible, depending on when lab test results are received, and this example highlights the importance of coordination and communication between the clinic and the lab during the study screening period.

As long as screening creatinine test results are available, it is not necessary to calculate CrCl prior to enrolment. True False

Plasma stored at the Screening Visit should be kept for all mothers who are screened, regardless of whether they enroll the study. True False

What are your questions?

IMPAACT 2010 Entry Visits Pick up from here AFTER Entry Visit Activity

Protocol References Section Title 6.2 Entry Visit Appendix 1 Schedule of Evaluations ─ Antepartum

Entry Visits Key operational reminders For eligible mother-infant pairs, enrollment must occur at 14-28 weeks gestation and within 14 days of the mother initiating ART in the current pregnancy All Entry Visit procedures are expected to be performed on the day of enrollment Procedures that may provide information relevant to eligibility for the study (e.g., medical history, physical examination) should be performed first, prior to final eligibility determination.

Entry Visits Key operational reminders Final eligibility determination and confirmation must precede enrollment Enrollment must precede prescribing of study drug Prescribing must precede dispensing of study drug Blood collection should ideally precede enrollment and must precede ingestion of the first dose of study drug

A mother is considered enrolled in the study when … She provides written informed consent She and her infant are found to meet all study eligibility criteria She and her infant are assigned SIDs by the Subject Enrollment System

An infant is considered enrolled in the study when … The infant’s mother provides written informed consent The mother and infant are found to meet all study eligibility criteria The mother and infant are assigned SIDs by the Subject Enrollment System The infant is born

What are your questions?